EkiYou-Study-2 : A National Multicentric Trial of the EkiYou Application for Insulin Bolus Calculation

Korábbi kezelés

• type 1 diabetic patients treated with any hypoglycemia-inducing agent other than insulin (including hypoglycemic sulfonamides and SGLT-2 inhibitors),
• diabetic ketoacidosis or severe level 3 hypoglycemia requiring third-party intervention within the 6 months prior to inclusion,
• participation in another clinical trial or administration of a non-authorised drug in the 4 weeks preceding the screening,

Más betegség

• pancreatic disease secondary to chronic ethanolism,
• known medical condition that, in the investigator's opinion, may interfere with the protocol,

Egyéb

• pregnant or breast-feeding women,
• insulin-resistant patient: prescribed daily insulin dose > 1 U/kg/day or > 200 U/day,
• patient with very low insulin requirements: daily insulin dose < 15 U/day,
• patient with gastroparesis,
• patient who cannot be monitored for 3 months,
• intellectual ability compromising use of the application, comprehension or completion of questionnaires,
• person taking part in another research study with an exclusion period still in progress,
• under guardianship or curatorship,
• imprisoned or otherwise deprived of liberty.

• be aged 18 or over,
• have type 1 or type 2 diabetes or diabetes secondary to pancreatic disease,
• have been treated with multi-injection basal/bolus insulin therapy for at least 6 months,
• using a compatible rapid insulin with the device Ekiyou such as : Novorapid, Humalog, Apidra, Asparte Sanofi, Fiasp or Lyumjev,
• using a compatible long-acting insulin with the device EkiYou such as : Lantus, Abasaglar, Toujeo, Levemir or Tresiba,
• have been using a continuous glucose monitoring device such as Dexcom G6, Dexcom One, Dexcom One+ or FreeStyle Libre for at least 3 months,
• have given their physician access to their glucose data via a glucose data management platform,
• for type 2 diabetic patients using an hypoglycemia-inducing agent other than insulin (including hypoglycemic sulfonamides and SGLT-2 inhibitors), have no change in dosage regimen for at least 3 months
• have recorded at least 70% of CGM data over a 14-day window close to the inclusion date,
• have at least one smartphone running Android 5.0 or higher or iOS 12.0 or higher connected to the internet and able to receive CGM data available to them on the day of the inclusion,
• able to read or use a smartphone with no visual impairment needing specific typography,
• for patients of childbearing potential, a pregnancy test must have been carried out prior to inclusion, or an effective and adequate method of contraception must be used,
• be affiliated to a French social security scheme.